[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582828":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":49,"collaborators":52,"id":56,"slug":20,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":80,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"baricitinib + steroid-sparing drug +\u002F- glucocorticoid taper","EXPERIMENTAL","* Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication\n* Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol",[13],"Drug: Baricitinib (LY3009104) 4 mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Baricitinib (LY3009104) 4 mg","baricitinib 4 mg tablet taken orally once daily",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Matthew C Baker, MD, MS","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Angie Aberia","CONTACT","650-723-8516","aberia@stanford.edu",{"name":32,"role":28,"phone":20,"phoneExt":20,"email":33},"Travis Deal","tdeal1@stanford.edu",[35],{"facility":5,"status":20,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Palo Alto","California","94304-2210","United States",{"type":41,"coordinates":42},"Point",[43,44],-122.14302,37.44188,{"lat":44,"lon":43},[47,48],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Matthew C. Baker","Assistant Professor of Medicine",[53],{"name":54,"class":55},"Eli Lilly and Company","INDUSTRY","100582828",false,"NCT06868381","A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis","Key Inclusion Criteria:\n\n* Diagnosis of cardiac sarcoidosis based on one of the following pathways:\n\n  * Histological Diagnosis\n\n    * Myocardial or extracardiac biopsy demonstrating non-caseating granuloma with no alternative cause identified AND\n    * Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND\n    * Exclusion of other causes for cardiac manifestations\n  * Clinical Diagnosis\n\n    * One or more of the following is present:\n\n      * Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n      * Unexplained reduced LVEF (\\\u003C 40%) and\u002For segmental wall motion abnormalities not related to coronary artery disease or another defined cause\n      * Unexplained sustained (spontaneous or induced) VT\n      * Mobitz type II 2nd degree heart block or 3rd degree heart block\n      * CT chest and\u002For FDG PET-CT showing features consistent with pulmonary sarcoidosis and\u002For hilar lymphadenopathy AND\n    * Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND\n    * Exclusion of other causes for cardiac manifestations\n* Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis\n* No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexate, leflunomide, azathioprine, or mycophenolate mofetil), and\u002For prednisone (or equivalent) at a dose of ≤ 20mg daily at Baseline\n\nKey Exclusion Criteria:\n\n* Receipt of a non-biologic DMARD or immunosuppressive agent other than methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, or glucocorticoids within 28 days prior to screening\n* Receipt of a bDMARD or tsDMARD, including non-depleting B-cell-directed therapy (eg, belimumab), T cell costimulatory blockade (eg, abatacept), TNF-alpha inhibition (eg, infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), interleukin-6 inhibition (eg, tocilizumab, sarilumab), interleukin-1 inhibition (eg, anakinra), JAK inhibition (eg, tofacitinib, upadacitinib, baricitinib), or other biologic immunomodulatory agent within 28 days prior to screening\n* Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) in the 6 months prior to screening; receipt of such a B cell-depleting agent in the period 6-12 months prior to screening is exclusionary unless B cell counts have returned to ≥ LLN\n* History of venous thromboembolism (VTE) or an increased risk for VTE\n* Current smoking\n* Estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Modification of Diet in Renal Disease Study (MDRD) equation\n* Blood tests at screening that meet any of the following criteria:\n\n  * Hemoglobin \\\u003C 7.5 g\u002FdL\n  * Neutrophils \\\u003C 1000\u002Fmm3\n  * Absolute lymphocyte count \\\u003C 500\u002Fmm3\n  * Platelets \\\u003C 100 x 109\u002FL\n* Subjects with the following abnormal liver function tests:\n\n  * Aspartate aminotransferase (AST) \\> 2x ULN\n  * Alanine aminotransferase (ALT) \\> 2x ULN\n  * Total bilirubin (TBL) \\> 2x ULN unless AST, ALT, and hemoglobin are within central laboratory normal range and the patient has a known history of Gilbert syndrome\n* Active, clinically significant infection at the time of Screening\n* Active malignancy or history of malignancy that was active within the last 5 years, except as follows:\n\n  * In situ carcinoma of the cervix following apparently curative therapy \\> 12 months prior to screening,\n  * Cutaneous basal cell or squamous cell carcinoma following apparently curative therapy, or\n  * Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent \\> 3 years prior to screening and without known recurrence or current treatment","ALL","18 Years","85 Years",{"count":66,"type":67},10,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:\n\n\\- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET\u002FCT?\n\nParticipants will:\n\n* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks\n* Visit the clinic every two to four weeks for checkups and tests\n* Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib",[73],"Cardiac Sarcoidosis",[75,76,77,78,79],"baricitinib","sarcoidosis","cardiac sarcoidosis","Janus kinase inhibitor","JAK inhibitor","NOT_YET_RECRUITING","2026-02-06",{"date":83,"type":84},"2026-02-10","ACTUAL",{"date":86,"type":67},"2026-04-01",{"date":88,"type":67},"2028-12-01",{"name":5,"class":6},1]